The Expression Dial: How CHRNA5 mRNA Levels Shape Nicotine Addiction Risk
The CHRNA5 gene on chromosome 15q25.1 encodes the alpha-5 subunit of the neuronal nicotinic
acetylcholine receptor — a critical component of the brain circuits that govern how aversive
nicotine feels at high doses. Most research on this region has focused on rs16969968, an amino
acid change (Asp398Asn) that blunts receptor function. But there is a second, molecularly
distinct mechanism at work: variation in how much CHRNA5 is made | rs588765 tags a cis-regulatory
haplotype that controls CHRNA5 transcription in brain and lung, independent of any protein-coding
change. rs588765 is the tag SNP for this second locus
(Locus 3, or Bin B), and it operates entirely through gene expression quantity rather than protein
quality.
The T allele at rs588765 is associated with approximately 4.7-fold higher CHRNA5 mRNA levels
compared to CC homozygotes — a large expression difference for a common variant. Because more
alpha-5 subunit is available, more functional α4β2α5 receptors assemble in key brain regions
including the medial habenula and interpeduncular nucleus. This in turn affects the sensitivity
of the aversive-response pathway to nicotine. When the non-risk amino acid variant (GG at
rs16969968) co-occurs with high expression (TT at rs588765) | The GG_TT diplotype shows OR=1.72
for nicotine dependence in European American brain tissue samples — a substantial risk elevation
from gene expression alone, independent of the coding change,
the risk for nicotine dependence is substantially elevated.
The Mechanism
The medial habenula–interpeduncular nucleus (MHb–IPN) axis is sometimes called the brain's
"nicotine brake": high nicotine concentrations activate α4β2α5 receptors in this pathway,
generating aversive signals (discomfort, nausea) that normally cap smoking. When alpha-5
subunit expression is high (T allele), more receptor complexes are assembled in this pathway,
and the brake becomes more tightly coupled to nicotine concentration — paradoxically increasing
sensitivity in ways that facilitate dependence at lower-dose exposure thresholds. When expression
is low (C allele), fewer receptors are available and the circuit operates differently.
The rs588765 intronic region appears to contain regulatory elements that control CHRNA5
transcription. Conditional analysis in cis-regulatory variant studies | rs3841324 and rs880395
— variants in the 2.5 kb upstream region — explain most of the expression signal, with rs588765
acting as a proxy tag in high LD with these functional elements in Europeans
suggests the true causal regulatory element lies in a 2.5 kb region upstream of CHRNA5, with
rs588765 serving as a high-LD proxy (r²=0.88 with rs3841324 in Europeans). The expression
effect replicates in both European American and African American prefrontal cortex, and has
been confirmed in lung tissue by GTEx, making this a biologically robust eQTL.
The Evidence
The key Wang et al. 2009 study | Analyzed CHRNA5 mRNA expression from 94 European American
brain samples alongside nicotine dependence case-control data; diplotype analysis revealed
independent effects of coding vs. expression variants
demonstrated that the GG_TT diplotype (non-risk coding variant + high expression) confers
OR=1.72 (95% CI 1.19–2.47) for nicotine dependence compared to GG_CC (non-risk coding + low
expression). This established that expression level and amino acid change are two distinct,
additive mechanisms at 15q25.1.
The independent GWAS signal at this locus was first confirmed at genome-wide significance by
Thorgeirsson et al. 2010 | Meta-analysis including >30,000 individuals; rs588765 was associated
only in conditional analyses after adjustment for rs16969968,
who showed that after conditioning on rs16969968, rs588765 achieves p=8.7×10⁻⁸ with
OR=1.27 (95% CI 1.16–1.38) for heavy versus light smoking. This conditionality confirms that
rs588765 is not simply tagging the rs16969968 haplotype, but represents an independent
biological signal that only becomes visible when the dominant coding-variant effect is removed
from the analysis.
In COPD patients, a genome-wide association study of smoking behaviors | Genome-wide scan in
COPD patients from the ECLIPSE cohort found rs588765 nominally associated with lifetime average
cigarettes per day (p=0.046), consistent with prior GWAS direction
found that rs588765 and rs578776 represent independent haplotypes associated with lifetime
average cigarettes per day, with consistent directional effects. In lung cancer risk specifically,
a meta-analysis of CHRNA variants | Epidemiological meta-analysis assigned strong evidence to
rs588765 for lung cancer risk under the recessive model in Caucasians (OR=1.19, p<0.001) and
moderate evidence for other genetic models assigned
strong evidence to rs588765 under the recessive model in Caucasian populations (OR=1.19,
95% CI 1.11–1.28).
The expression effect is population-consistent. Cross-ancestry replication | Expression QTL
analysis in both European and African American prefrontal cortex showed significant association
with T allele at rs588765 in both groups; African p=1.10×10⁻⁴, European p=3.11×10⁻¹⁰
confirmed the T allele increases CHRNA5 expression in African Americans (p=1.10×10⁻⁴) as well
as Europeans (p=3.11×10⁻¹⁰), though the LD structure and proxy relationships differ somewhat
by ancestry.
Practical Actions
The independent expression-level signal at rs588765 adds information beyond what rs16969968
captures. Carrying the TT genotype at rs588765 on a GG background at rs16969968 means your
risk for nicotine dependence is elevated through the expression pathway even without the
coding-change risk. The two loci have additive effects: a person carrying both the rs16969968
AA genotype and the rs588765 TT genotype has the highest combined burden at this cluster.
For never-smokers, TT homozygotes should be aware that their elevated CHRNA5 expression may
confer added vulnerability to nicotine dependence if they initiate tobacco use. For current
smokers carrying TT, standard cessation pharmacotherapy (varenicline or bupropion) that works
independently of CHRNA5 expression levels is the preferred approach, as the expression-level
effect cannot be directly modified. The lung cancer signal at this locus provides additional
motivation for earlier screening discussions in individuals with substantial smoking history.
Interactions
rs588765 is in low linkage disequilibrium with rs16969968 (the coding D398N variant), meaning
the two provide independent genetic risk information. The critical biological insight is
haplotype-level: the highest-risk diplotype is AA_TT — homozygous for both the function-reducing
coding change at rs16969968 AND the high-expression allele at rs588765. The GG_CC diplotype
(non-risk coding + low expression) appears to be the most protective combination.
In terms of proxy relationships, rs588765 is in high LD with rs880395 (r²≈0.88 in Europeans),
which several analyses identify as a more proximal regulatory variant. GeneOps includes both
independently because they behave differently in non-European populations where LD patterns
diverge. The third independent locus at 15q25.1 is rs578776 (Locus 2, associated with reward
sensitivity), which is distinct from rs588765 in both mechanism and genomic position.
All Genotypes
Low CHRNA5 expression — protective expression profile for this independent locus
You carry two copies of the C allele, associated with lower CHRNA5 mRNA expression in brain and lung tissue. About 37% of Europeans share this genotype. This expression profile is protective relative to TT carriers at this specific locus: the Wang et al. diplotype analysis found that GG_CC (non-risk coding variant + low expression) represented the reference group with lowest nicotine dependence risk from the expression mechanism. Note that your overall nicotine dependence risk also depends on your rs16969968 genotype — carrying the CC genotype here provides a partial protective buffer, but does not override the coding-change risk from Locus 1 if present.
One high-expression allele — moderately elevated independent risk via CHRNA5 expression
You carry one T allele, giving you intermediate CHRNA5 mRNA expression levels. About 48% of Europeans share this genotype, making it the most common. The T allele increases CHRNA5 expression, and heterozygotes show expression levels between CC and TT homozygotes. In conditional GWAS analysis, the T allele confers OR=1.27 for heavy versus light smoking after adjustment for rs16969968 — meaning this represents genuine independent biological risk from the expression mechanism, not simply a proxy for the coding-change locus. Your combined risk depends on what you carry at rs16969968 as well; the two loci have additive effects.
High CHRNA5 expression — elevated independent risk for nicotine dependence and lung cancer via expression mechanism
You carry two copies of the T allele, associated with approximately 4.7-fold higher CHRNA5 mRNA expression in brain and lung tissue compared to CC homozygotes. About 15% of Europeans share this genotype (much rarer in East Asians at ~0.3%). The Wang et al. diplotype study found that individuals with the non-risk coding variant but high expression (GG_TT diplotype) had OR=1.72 for nicotine dependence compared to the low-expression reference group — a substantial independent risk from the expression pathway alone. Your combined risk at the 15q25.1 locus also depends on your rs16969968 genotype; if you carry the AA or AG genotype there as well, your total burden across both mechanisms is additive.